7 results on '"Kronbichler, Andreas"'
Search Results
2. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis.
- Author
-
Oh, SuA, Purja, Sujata, Shin, Hocheol, Kim, Min Seo, Park, Seoyeon, Kronbichler, Andreas, Smith, Lee, Eisenhut, Michael, Shin, Jae Il, and Kim, Eunyoung
- Subjects
COVID-19 pandemic ,COVID-19 vaccines ,VACCINE safety ,IMMUNE response ,NEUTRALIZATION tests ,VACCINE effectiveness - Abstract
The most effective method of limiting the coronavirus disease pandemic of 2019 (COVID-19) is vaccination. For the determination of the comparative efficacy and safety of COVID-19 vaccines and their platforms during the pre-Delta era, a systematic review and network meta-analysis was conducted. The MEDLINE, Embase, and MedRxiv databases were searched, and the gray literature was manually searched up to 8 July 2021. The review includes the phase II and III randomized controlled trials (RCTs) that assessed the efficacy, immunogenicity, and safety of the COVID-19 vaccines. The network meta-analysis used a Bayesian model and used the surface under the cumulative ranking to rank the comparisons between the vaccines. All included studies were quality appraised according to their design, and the heterogeneity of the analyses was assessed using I2. In terms of vaccine efficacy, the mRNA-1273 vaccine ranked the highest, and the CoronaVac vaccine ranked the lowest. The mRNA-1273 ranked the highest for neutralizing antibody responses to live SARS-CoV-2. The WIV04 vaccine was associated with the lowest incidence of both local and systemic adverse reactions. All studies except one had a low to moderate risk of bias. The mRNA platform vaccines showed higher efficacy and more adverse reactions than the other vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.
- Author
-
Stevens, Kate I, Frangou, Eleni, Shin, Jae I l, Anders, Hans-Joachim, Bruchfeld, Annette, Schönermarck, Ulf, Hauser, Thomas, Westman, Kerstin, Fernandez-Juarez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Turkmen, Kultigin, Kooten, Cees van, McAdoo, Stephen P, Tesar, Vladimir, Segelmark, Mårten, Geetha, Duvuru, Jayne, David R W, Kronbichler, Andreas, and (EUVAS), Immunonephrology Working Group (IWG) of the European Renal Association (ERA) and the European Vasculitis Society
- Subjects
COVID-19 ,COVID-19 vaccines ,VACCINE effectiveness ,BOOSTER vaccines ,HUMORAL immunity ,KIDNEY diseases - Abstract
Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination.
- Author
-
Göndör, Gabor, Ksiazek, Sara H, Regele, Heinz, Kronbichler, Andreas, Knechtelsdorfer, Maarten, and Säemann, Marcus D
- Subjects
COVID-19 vaccines ,COVID-19 ,GLOMERULONEPHRITIS ,KIDNEY glomerulus diseases ,NEPHRITIS - Abstract
Membranoproliferative glomerulonephritis (MPGN) comprises a histologic pattern of glomerular injury with different underlying diseases. Here we report on a 47-year-old female with rapidly progressive glomerulonephritis (RPGN) on top of a previously diagnosed idiopathic MPGN after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA vaccine. After aggressive immunosuppression her serum creatinine returned to normal values, along with reduction of proteinuria. Recently, numerous publications have reported an association of glomerular diseases with COVID-19 vaccination. Our case presents to the best of our knowledge the first occurrence of possible association of COVID-19 mRNA vaccination with a crescentic form of MPGN. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.
- Author
-
Kronbichler, Andreas, Anders, Hans-Joachim, Fernandez-Juárez, Gema Maria, Floege, Jürgen, Goumenos, Dimitrios, Segelmark, Mårten, Tesar, Vladimir, Turkmen, Kultigin, Kooten, Cees van, Bruchfeld, Annette, and Association), the Immunonephrology Working Group of the ERA-EDTA (European Renal Association—European Dialysis and Transplant
- Subjects
- *
COVID-19 , *COVID-19 vaccines , *KIDNEY diseases , *TYPE I interferons - Abstract
Open in new tab Download slide Open in new tab Download slide Coronavirus disease 2019 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of severe acute respiratory syndrome coronavirus 2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. Here, members of the Immunonephrology Working Group of the European Renal Association–European Dialysis and Transplant Association discuss 13 frequently asked questions regarding the safety and efficacy of the most promising vaccine candidates. Post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms and disease activity following the administration of COVID-19 vaccines. Some of the candidates induce signalling pathways, which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favour the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies, patients might be protected by a sufficient cellular immune response capable of reducing the severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated and it is particularly important to discuss strategies to improve vaccine response with these patients. Distancing and shielding measures remain important, as not all vaccines fully protect from coronavirus infection. In-depth information about the most pressing vaccine questions is essential to reduce vaccine hesitancy of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
- Author
-
David Jayne, Federico Alberici, Mårten Segelmark, Wladimir Szpirt, Fernando C. Fervenza, Annette Bruchfeld, Andreas Kronbichler, Vladimir Tesar, Kronbichler, Andreas [0000-0002-2945-2946], Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository
- Subjects
2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Immunologic Factors ,MEDLINE ,ANCA-Associated Vasculitis ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Antibodies, Antineutrophil Cytoplasmic ,Remission induction ,immune system diseases ,hemic and lymphatic diseases ,Urologi och njurmedicin ,medicine ,Research Letter ,Urology and Nephrology ,Humans ,cardiovascular diseases ,AcademicSubjects/MED00340 ,skin and connective tissue diseases ,Transplantation ,business.industry ,Remission Induction ,COVID-19 ,respiratory tract diseases ,Nephrology ,Preparedness ,Immunology ,Rituximab ,business ,medicine.drug - Abstract
COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.
- Published
- 2021
7. The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
- Author
-
Annette Bruchfeld, David Jayne, Duvuru Geetha, Andreas Kronbichler, Maria C. Cid, Allyson Egan, A. Mahr, Ingeborg M. Bajema, Rona M Smith, Ulf Schönermarck, Hans-Joachim Anders, Kronbichler, Andreas [0000-0002-2945-2946], Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository
- Subjects
medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Population ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Review ,Antibodies, Antineutrophil Cytoplasmic ,Immune system ,Internal medicine ,Pandemic ,medicine ,Humans ,Immunology and Allergy ,education ,Pandemics ,education.field_of_study ,biology ,SARS-CoV-2 ,business.industry ,Mortality rate ,COVID-19 ,medicine.disease ,biology.protein ,Rituximab ,Antibody ,Vasculitis ,business ,medicine.drug - Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis following COVID-19, but mortality is higher than in the general population and comparable to patients undergoing haemodialysis or kidney transplant recipients (reported mortality rates of 20–25%). Delays in diagnosis have been reported, which are associated with sequelae such as dialysis-dependency. Management of ANCA-associated vasculitis has not changed with the aim to suppress disease activity and reduce burden of disease. The use of rituximab, an important and widely used agent, is associated with a more severe hospital course of COVID-19 and absence of antibodies following severe acute respiratory syndrome (SARS)-CoV-2 infections, which prone patients to re-infection. Reports on vaccine antibody response are scarce at the moment, but preliminary findings point towards an impaired immune response, especially when patients receive rituximab as part of their treatment. Seropositivity was reported in less than 20% of patients when rituximab was administered within the prior six months, and the antibody response correlated with CD19+ B-cell repopulation. A delay in maintenance doses, if disease activity allows, has been suggested using a CD19+ B-cell guided strategy. Other immunosuppressive measures, which are used in ANCA-associated vasculitis, also impair humoral and cellular vaccine responses. Regular measurements of vaccine response or a healthcare-policy time-based strategy are indicated to provide additional doses (“booster”) of COVID-19 vaccines. This review summarizes a recent educational forum and a recent virtual meeting of the European Vasculitis Society (EUVAS) focusing on COVID-19.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.